|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EXTRACELLULAR MATRIX, CELL INTERACTIONS
CIHR Group in Skeletal Development and Remodeling, 1Department of Biochemistry, 2Department of Physiology and Pharmacology, and 3Division of Oral Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada
Submitted 19 November 2007 ; accepted in final form 1 May 2008
| ABSTRACT |
|---|
|
|
|---|
fibroblast; cell adhesion; focal adhesion kinase; arginine-glycine-aspartate
Fibronectin (FN), a dimer consisting of two 220- to 250-kDa monomer subunits, is expressed throughout the growth plate (24). It stabilizes ECM structure by binding multiple matrix components such as collagens and proteoglycans. It mediates cell adhesion through a central RGD (Arg-Gly-Asp) motif and various non-RGD sequences (40). Although mice with cartilage-specific deletion of FN have no apparent phenotype under standard laboratory conditions (3), numerous studies have shown a role for FN (54) or FN-binding integrins, for example,
5β1- (11, 15) and β1-containing integrins (3), in regulating chondrocyte development.
Unlike FN, which is expressed ubiquitously, bone sialoprotein (BSP) expression is essentially restricted to mineralized tissues (14). BSP has extensive posttranslational modifications (PTMs) that add upwards of 23 kDa to the 34-kDa molecular mass of the core protein (59, 60). This monomeric protein has three well-characterized, functionally distinct domains that, similar to FN, stabilize ECM structure: an NH2-terminal collagen binding site (47), two unique central glutamic acid-rich regions capable of binding mineral hydroxyapatite (19, 44), and a COOH-terminal integrin-binding RGD domain (23, 33, 44) that binds
vβ1- (26),
vβ3- (37) and
vβ5-integrins (46). BSP is synthesized by hypertrophic chondrocytes at a time when the hypertrophic zone of the growth plate undergoes mineralization, vascular invasion, and eventual replacement by a bone matrix (14). In vitro and in vivo assays have linked BSP to the aforementioned processes (5, 20, 49, 53), but it is not known whether growth plate chondrocytes are responsive to BSP. Furthermore, it is not known how cells use intracellular signaling intermediates to control their cellular responses to BSP and how these intracellular signaling molecules control similar responses to FN.
BSP and FN are examples of ECM proteins that bind different cell surface integrins and form functional units of cell adhesion termed focal adhesions. Signals emanating from focal adhesions determine the cellular response to ECM proteins (31). Focal adhesion kinase (FAK) interacts directly with the cytoplasmic tail of various transmembrane receptors and has been implicated in regulating many adhesion-related functions (34). Many of these FAK functions are regulated by Src, which coactivates FAK and forms a dual FAK-Src signaling complex through the binding of SH2 domain of Src to a phosphotyrosine at Y397 of FAK (35). We have shown FAK-Src signaling as negative regulators of early chondrogenesis (7, 39), but it is not known how this signaling complex is regulated in growth plate chondrocytes by different integrin-binding proteins and whether chondrocyte adhesion to and spreading on different ECM proteins is regulated by FAK-Src signaling.
Members of the Rho family of small GTPases constitute another set of proteins involved in cellular responses to adhesion (6, 21, 41). Rho GTPases are major regulators of the cell cytoskeleton and act upstream and downstream of integrin ligands (6, 31). The Rho GTPases cycle between active GTP-bound forms and inactive forms following the hydrolysis of bound GTP into GDP (6). RhoA and Rac1 are common examples of Rho GTPases (6). Our in vitro studies have demonstrated important roles of RhoA and Rac1 in chondrocyte differentiation (51, 55, 57, 58). We have also shown that Rac1-null chondrocytes display reduced adhesion and spread on different ECM surfaces (52). However, it is not known how Rho and an effector of Rho, Rho kinase (ROCK), regulate chondrocyte adhesion and spreading on different ECM substrates.
Measuring cell adhesion and spreading on adsorbed ECM components in the two-dimensional context of tissue culture can be used as indicators to gauge the ability of these proteins to promote cell contact and consequently alter cell behavior (10, 36). Thus studying cell adhesion and spread to ECM components and signaling pathways affecting these processes in vitro are directly relevant to understanding how ECM proteins contribute to maintaining tissue architecture in vivo. With this in mind, the objectives of this study were fourfold: 1) determine to what extent actin polymerization controls cell adhesion to and contact with FN- and BSP-coated surfaces; 2) use adhesion and spreading dynamics to define chondrocyte sequence-function relationships with BSP; 3) determine how FAK-Src and Rho-ROCK signaling regulate chondrocyte adhesion and spreading on FN- or BSP-coated surfaces, and 4) determine differences in the manner that chondrocytes and fibroblasts use Rho-ROCK signaling to control cell adhesion and morphology.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Cell culture. Primary chondrocytes were isolated and cultured as previously described (30, 55). Briefly, impregnated CD1 mice (Charles River Laboratories) were euthanized with CO2, and embryos were collected at 15.5 days post coitus, when long bones mainly consist of chondrocytes. The use of mice was approved by the University of Western Ontario Council on Animal Care. Forelimb bones (radius, ulna, and humerus) were removed from the embryos, and cells were isolated by sequential digestion with trypsin-EDTA (Invitrogen) and Collagenase P (Roche) to remove the perichondrium and isolate chondrocytes, respectively. Undigested mineralized collars were removed, and the remaining cells plated at 5.0 x 105 cells/well in a six-well plate (Nunc) until use. For all experiments, cells were used without subculturing and between 4 to 8 days postisolation. Cells were maintained in DMEM containing 10% FBS (Invitrogen), 0.5 mM glutamine, 25 U/ml penicillin, and 25 µg/ml streptomycin (hereafter referred to as chondrocyte medium) at 37°C in a humidified atmosphere with 5% CO2. NIH 3T3 were maintained as described (50) and used between passages 8 to 15.
Protein expression and purification. Recombinant BSP (rBSP) was expressed and purified as previously described (48). Briefly, Escherichia coli strain BL21 (DE3) cells were transformed with a pET28 vector containing the rat BSP cDNA sequence with a His tag and a kanamycin-resistant gene. Mutant rBSP with the RGD domain mutated to KAE (Lys-Ala-Glu) was produced as described (20) but in the pET28 vector. For expression of recombinant protein, kanamycin-resistant colonies were propagated in Luria broth at 37°C. After expression was induced, rBSP was purified by passing cellular extracts through Ni affinity, ion-exchange, and size-exclusion columns. Protein identity was confirmed by amino acid analysis, SDS-PAGE, and mass spectroscopy. Native BSP (nBSP) was extracted from crushed rat tibias using 0.5 M EDTA, after sequential washing with PBS and 4 M guanidine hydrochloride (all solutions contained Tris·HCl, pH 7.4, and protease inhibitors). The extracted protein was purified by ion-exchange and size-exclusion chromatography according to our published protocol (18).
Cell adhesion assay. Proteins of interest were coated overnight (300 or 100 µl/well for 24-well or 96-well plates, respectively) at various concentrations in triplicate wells on Falcon tissue culture plates (BD Biosciences) at 4°C. For immunofluorescence, 12-mm diameter glass slides (Fisher Scientific) were placed in each well of a 24-well plate and coated as above. Before the assay, each well was washed with PBS to remove excess protein and blocked with adhesion medium (0.2-µm filtered 2% BSA-DMEM containing 0.5 mM glutamine, 25 U/ml penicillin, and 25 µg/ml streptomycin) to prevent nonspecific cell adhesion. The plates were incubated at 37°C for 1 h. Concurrently, cells were disadhered by incubation with trypsin-EDTA for 3 min at 37°C. Trypsin was inactivated by addition of chondrocyte medium, and cells were harvested by centrifugation. The cell pellet was washed with adhesion medium once to remove residual serum and resuspended in adhesion medium. Cells were left in suspension for 60 min before being plated. Chondrocytes were plated at 250 cells/mm2. For experiments involving alterations to the actin cytoskeleton, cells were incubated with adhesion medium containing 3 µM cytochalasin D (CD), 10 µM PP2, or 30 µM Y27632 for 60 min before being plated. In experiments using C3, cells were incubated with 6 µg/ml of this Rho-inactivating toxin for 2 h before cells were plated. Corresponding controls were incubated in adhesion medium alone. Other concentrations of inhibitors and toxins were tried, but the aforementioned concentrations are commonly used and were found to give potent biological responses. To obtain perimeter measurements reflective of each treatment for experiments using Rho and ROCK inhibitors, cell-plating densities were reduced to 140 viable primary chondrocytes/mm2 and 170 viable NIH3T3 cells/mm2. This lower density reduced cell clumping. After incubation at 37°C in a humidified atmosphere with 5% CO2 for 60 min (unless stated otherwise), weakly adhered cells were removed by washing each well with adhesion medium. Cells were then fixed with 4% formalin in PBS for 20 min, permeabilized with 0.1% Triton-X100 in PBS for 10 min, and washed twice with PBS before storage for up to a month at 4°C in the dark with PBS containing 14 nM rhodamine-phalloidin and 86 nM DAPI. Before analysis, excess fluorescent stain was washed away with three PBS washes. Random micrographs of cells adhered to different coats were taken using an inverted Leica DMIRE2 microscope equipped for fluorescence detection attached to a Hamamatsu ORCA-ER digital camera. Each well had at least five micrographs taken representing a 5% sampling of total well area. Pictures were analyzed using OpenLab software. Binary masks were generated for each fluorescence dye (rhodamine-phalloidin and DAPI). Masks generated from pictures of DAPI-stained cells were used to count attached cells; each nuclei was counted as an attached cell. Masks generated from pictures of rhodamine-phalloidin-stained cells were used to measure average cell spread and average cell perimeter. Cell spread was computed as total area of spread cells per micrograph per number of DAPI-stained nuclei from corresponding micrograph (expressed as µm2/cell). Cell perimeter was computed as total perimeter of identified objects in rhodamine-stained cells per micrograph per number of DAPI-stained nuclei from corresponding micrograph (expressed as µm/cell). Although the cell perimeter measurements are not absolute measurements of cell perimeter, these values represent the protrusiveness of adhered cells and are values that are reflective of each treatment.
Quantification of adsorbed protein. To determine the amount of protein adsorbed to the plate surface, 96-well Falcon plates were coated with 10 µg/ml solutions of FN, rBSP, and nBSP. Each well was coated in triplicate at 150 µl/well. After 14–16 h at 4°C, the coating solution was removed and mixed with a single 150-µl PBS wash solution from the corresponding well used to remove loosely bound protein. Of this 300- µl mixture, 150 µl were mixed with 150 µl of Pierce Micro BCA working reagent in a microfuge tube, incubated at 60°C for 1 h, and absorbance measured at 562 nm. Individual standard curves were made using each protein under identical conditions. The protein content of the recovered solution used to coat each well was subtracted from the total protein initially plated to determine the amount of protein adsorbed to each well. The experiment was repeated three times.
In addition, an ELISA was used to determine relative levels of protein coating as modified from Tye et al. (47). Briefly, 24-well Falcon plates were coated with 2–20 µg/ml of FN or rBSP in triplicate wells as before. Wells were blocked with adhesion medium for 1 h at 37°C. Plates were then incubated overnight at 4°C with primary antibody (anti-His at 1/100,000 or anti-FN at 1/40,000) and subsequently detected with the corresponding horseradish peroxidase-linked secondary antibody (anti-mouse at 1/4,000 or anti-rabbit at 1/2,000) incubated for 1 h at room temperature. Addition of 0.4 ml/ ml ortho-phenylenediamine in phosphate-citrate buffer (200 nM Na2HPO4, 100 mM citric acid at pH 5) to each well initiated a colorimetric reaction that was stopped 4 min later with 2.5 M H2SO4. The absorption of the resulting solution was measured at 492 nm using a Safire2 Microplate Detection System. Relative coating indexes were obtained by dividing all absorbencies by the absorbance measured at the 2 µg/ml coating for each protein. The experiment was repeated three times.
Immunofluorescence. All steps up to and including cell fixation and permeabilization were followed as described in the cell adhesion protocol above. Washes, incubations with primary and secondary antibodies, rhodamine-phalloidin and DAPI, mounting with Vectashield antifade mounting media and sealing slides were as described (52). Pictures were obtained using an upright Leica DMRA2 microscope equipped for fluorescence detection with a Q-imaging Retiga Ex 12-bit camera. Images were processed using OpenLab and ImageJ (NIH) software. Each staining was performed on triplicate slides and repeated at least twice. No fluorescent staining was observed when staining with secondary antibody alone (data not shown) nor when slides were reacted with solutions containing primary antibody and target immunogenic peptide indicating specificity of the primary anti-phospho-FAK Y397 antibody for the target protein (data not shown).
Collection and preparation of cell lysate. As in the cell attachment assays in Cell adhesion assay, Falcon T-175 flasks were coated with protein solutions overnight and blocked with adhesion medium. After the incubation of 15 x 106 chondrocytes per flask on various protein coats at 37°C for 1 h, adhered cells were scraped into 1 ml of RIPA buffer [50 mM Tris·HCl, pH 7.4, 150 mM NaCl, 1% NP40, 0.25% sodium deoxycholate, 2 mM PMSF, 8 mM Na3VO4, 2 mM NaF, and 1 protease inhibitor cocktail tablet (Roche) per 25 ml of buffer] on ice. Adhesion medium from each flask containing nonadhered cells was collected and centrifuged. These cell pellets were mixed with adhered cell lysates from the corresponding treatments. Lysates were stored at –80°C until use. Before use, two freeze-thaw cycles were used to further ensure cell lysis. This crude lysate was centrifuged to remove insoluble cellular debris, and the supernatant was used for subsequent experiments.
Immunoprecipitation and Western blot analyses. The Catch and Release Reversible Immunoprecipitation System (Upstate) was used to precipitate FAK with mouse anti-FAK antibodies from precleared cell lysates according to the manufacturer's instructions. Lysates containing equal cell numbers were used for each immunoprecipitation. After this initial FAK pulldown, this same lysate was subjected to another round of immunoprecipitation with mouse anti-FAK antibodies to assess the efficiency of the original FAK pulldown. Captured FAK was resolved on 10% SDS-polyacrylamide gels and transferred to polyvinyldifluoride membrane (Amersham Biosciences) using the Bio-Rad Trans-Blot SD Semi-Dry electrophoretic transfer cell. For immunoblotting of β-actin in the immunoprecipitation loading control, 7.5 x 105 cells were loaded per lane. After a 5% BSA block, membranes were probed with relevant antibodies and detected using ECL Western Blotting Detection kit (Amersham Biosciences). Blots were visualized using ChemiImager5500 (AlphaInnotech). Three independent trials were performed.
Statistical analyses. Numerical data were analyzed using Graphpad 4.0 software where possible. To determine statistical differences among means, one-way ANOVA was performed. If a statistically significant difference was determined (P < 0.05), a Bonferroni multiple contrasts test was performed to determine which pairs of means were statistically different.
| RESULTS |
|---|
|
|
|---|
|
To determine the dependence of adhesion and spread on coating concentration, chondrocytes were plated on a range (0.1–20 µg/ml) of FN and rBSP concentrations for 1 h (Fig. 1, D and E). Maximal chondrocyte adhesion was observed starting at 2 µg/ml for FN and 5 µg/ml for rBSP. Maximal cell spread was only observed when coating with at least 5 µg/ml for each protein. This cell spread was not statistically different from the cell spread measured at higher coating concentrations (P > 0.05). Consistent with the time-dependent data, more cell spread and thus more cell contact were observed on FN-coated surfaces than rBSP-coated surfaces. Of note, similar cell spread was observed for chondrocytes bound to rBSP at 10 µg/ml and FN at 2 µg/ml. These data establish that maximal adhesion and cell spread are observed within 1 h in chondrocytes plated on FN- or rBSP-coated at 10 µg/ml.
Attachment to BSP is entirely dependent on the RGD domain. PTMs of proteins have been implicated in modulating cellular activities. Previous studies have shown that BSP extracted from bone has numerous PTMs (13, 43, 59, 60). We therefore examined whether PTMs present on native, bone-extracted BSP could regulate chondrocyte adhesion and spread. To ensure that nBSP and rBSP had similar binding properties to tissue culture plastic, we showed that there was no significant difference in coating between native and recombinant BSP (as discussed above). There was no difference in chondrocyte adhesion (Fig. 2A) to or spreading (Fig. 2B) on native or rBSP. These results suggest that PTMs on nBSP do not play a role in the adhesion or spread of chondrocytes to BSP.
|
Actin polymerization is essential for chondrocyte and fibroblast spreading on FN and BSP. Numerous experiments have shown that elements of the cell cytoskeleton can act downstream of integrins in response to ECM proteins (25, 32). We wanted to determine to what extent actin microfilaments mediate cellular contact with surfaces coated with FN and BSP. Our data demonstrated that chondrocytes attach to and spread on FN and rBSP with distinct F-actin structures but retain a rounded-shape on BSA (Fig. 3A). Note that the actin cytoskeleton clearly outlines the shape of the cell and can be used to perform morphometric analyses. Incubation with the F-actin capping toxin CD abolished chondrocyte spreading on FN (data not shown) and rBSP (Fig. 3A). Similar results were obtained with actin sequestering agent Latrunculin B (data not shown). Whereas chondrocyte (Fig. 3B) and fibroblast (Fig. 3D) adhesion were unaffected by repression of actin polymerization, spreading of both cell types (Fig. 3, C and E, respectively) were significantly reduced (P < 0.001) when compared with controls and similar to levels of spread observed for cells on BSA. These results indicate that whereas cell adhesion is independent of actin polymerization, cell spreading on FN or BSP is completely dependent on the ability of chondrocytes and fibroblasts to polymerize actin.
|
|
Inhibition of Rho alters cell morphology and increases cell spread on BSP. Since Rho GTPases have long been known to alter actin-based cytoskeletal responses, we were interested in determining whether Rho was modulating parameters of chondrocyte morphology (cell spreading area and cell perimeter) in response to surfaces coated with FN or BSP. To investigate this, cells were incubated with the Rho-inactivating toxin C3 before these cells were plated on substrate-coated surfaces. Regardless of the coating substrate, C3-treated chondrocytes lost intracellular actin fibers and formed prominent actin structures at the cell periphery (Fig. 5). Actin remodeling induced by C3 treatment did not alter cell adhesion (supplementary Fig. 1A) but did differentially change the morphology of cells on FN and BSP. Whereas cell spread (Fig. 6A) did not significantly change on FN (P > 0.05), C3 did cause the formation of membrane protrusions that significantly increased the cell perimeter (P < 0.01; Fig. 6B). Chondrocytes treated with C3 and adhered to rBSP increased cell spread (Fig. 6A) and cell perimeter (Fig. 6B) to levels not statistically different (P > 0.05) from those observed for FN.
|
|
ROCK inhibition has different consequences in chondrocytes and fibroblasts. ROCK is a serine-threonine kinase that is directly activated by GTP-bound Rho. To determine whether ROCK could act downstream of Rho and mimic the effects of Rho inhibition in chondrocytes, chondrocytes were incubated with the ROCK inhibitor Y27632 before cells were plated on coated surfaces. As noted with Rho inhibition, ROCK inhibition dramatically altered F-actin arrangement within cells in a FN- or rBSP-dependent manner (Fig. 7) but did not change the number of adhered cells (supplementary Fig. 2A). FN-adhered chondrocytes treated with the ROCK inhibitor did not alter cell spread (P > 0.05; Fig. 8A) when compared with control cells but did develop lengthy actin-rich membrane protrusions that significantly (P < 0.001) increased cell perimeter (Fig. 8B), similar to Rho inactivation. Another similarity with Rho inhibition in chondrocytes was the ability of ROCK inhibition in rBSP-adhered chondrocytes to increase cell spread to levels not statistically different from cells adhered on FN. Plating Y27632-treated chondrocytes on surfaces coated with less FN did not increase cell spread (supplementary Fig. 3), suggesting Rho-ROCK regulation of cell spreading is unique to chondrocytes plated on BSP. Thus, in terms of cell spread and perimeter, and for each ECM molecule, ROCK inhibition was able to mimic the effects of Rho inhibition in chondrocytes.
|
|
| DISCUSSION |
|---|
|
|
|---|
The main difference noted in this study is decreased cell spread on BSP-coated surfaces compared with cells bound to FN, irrespective of time. A possible explanation for this is that FN-coated surfaces provide more adhesive contacts compared with BSP-coated surfaces, likely because FN has numerous well-characterized cell adhesion sites (40). Some studies have identified non-RGD regions within BSP that mediate cell adhesion (33, 44). BSP is a member of the small integrin ligand N-linked glycoprotein (SIBLING) family of ECM molecules (42). It has also been shown that the extensive PTMs within the SIBLING family regulate various cell functions including adhesion (42). However, we demonstrate that the PTMs of nBSP do not alter the adhesion or spread of chondrocytes. Instead, growth plate chondrocyte and fibroblast adhesion to BSP is entirely dependent on the RGD sequence. To rule out the possibility that decreased cell spread on BSP was a result of less BSP bound to surfaces, we showed that on a mole-per-mole basis, 16x more BSP adsorbed to surfaces compared with FN. Hence, the vast molar excess of BSP adsorbed on surfaces implies that other mechanisms restrict chondrocyte spreading and thus cellular contact with BSP-coated surfaces.
Establishing that a functional actin cytoskeleton is an absolute requirement for cell spread on FN and BSP independent of cell adhesion, we hypothesized that intracellular signaling molecules known to regulate actin organization are responsible for the lower level of cell spreading on BSP when compared with FN. The FAK-Src signaling complex was one prime candidate for such a function. The ability of FAK to regulate cell adhesion is not universal but is dependent on the cell type and the adhering matrix (22). We found that FAK-Src inhibition decreased chondrocyte adhesion to both FN and BSP. FAK controls focal adhesion dynamics and cell spread (34) consistent with the localization of activated FAK in the perimeter of adhered chondrocytes on both FN and BSP in our study. Inhibition of FAK-Src signaling also decreased chondrocyte spread to both FN and BSP. However, FAK activation did not discriminate between different adhesive matrices nor did it correlate with the degree of cell spreading. Our results suggest that FAK-Src signaling act as positive regulators of chondrocyte adhesion and spreading to both FN and BSP and is likely a part of the basal adhesion and spreading machinery of chondrocytes but is not responsible for the difference in cell spread between FN and BSP.
In contrast to FAK-Src signaling, Rho signaling has been implicated as both a positive and negative regulator of cell spread in numerous models. In astrocytes, active Rho is responsible for spreading and flattening of cells in response to lysophosphatidic acid and thrombin (45), whereas multinucleated monocytes use active Rho for cell retraction and to negatively regulate cell spread by completely dissolving fibrillar actin structures (38). We identify Rho as a mediator of different spreading responses to particular ECM components. Inhibition of Rho increased spreading on BSP but not on FN, without affecting cell adhesion. Recent work by Flevaris et al. (12) have identified a molecular switch in which calpain-dependent cleavage of β3-integrin in fibrinogen-adhered cells switches the cellular response from cell spread to cell retraction by relief of Rho inhibition. Interestingly, studies by Chen et al. (9) have shown inhibition of Rho signaling to increase cell spread to cell-secreted and serum-adsorbed components independently of FAK signaling, which would agree with our findings.
ROCK inhibition in chondrocytes was able to corroborate our findings with Rho inhibition, namely, an increase in spreading to BSP and membrane protrusiveness to FN. However, ROCK inhibition was not able to mimic all effects of Rho inhibition. Rho inhibition disturbed the actin cytoskeleton in both chondrocytes and fibroblasts, leading to the loss of intracellular actin fibers and prominent filamentous actin structures at the cell periphery. This was not observed with ROCK inhibition in either cell type. ROCK inhibition in fibroblasts adhered to FN, or BSP increased membrane protrusions, which were not observed in Rho-inhibited fibroblasts. This is intriguing considering Rho inhibition increased cell spread in BSP-adhered fibroblasts while Rho and ROCK inhibition increased cell spread in BSP-adhered chondrocytes. Based on the more drastic phenotype observed with ROCK inhibition compared with Rho inhibition, we cannot rule out factors influencing inhibitor efficacy (for example, cellular uptake of inhibitors). However, the apparent differences in Rho and ROCK functions are not without precedent. Different cell types are known to use Rho effectors in different capacities (16). At least for some observed Rho-dependent phenotypes, other downstream effectors of Rho, for example mDia (6), may mediate these effects.
Our work has important implications for understanding chondrocyte behavior in physiological, pathological, and in vitro conditions. By identifying FAK/Src signaling as positive regulators of chondrocyte adhesion to matrix proteins, we provide a potential mechanism for enhanced chondrogenesis observed by reducing FAK/Src activity in chondrocyte precursors (39) and chondrocytes (7). We show that FAK/Src inhibition decreases chondrocyte-matrix interactions. Cell-matrix interactions negatively regulate early chondrogenic events where tight cell-cell adhesion is essential as opposed to later differentiation events, which depend on close cell-matrix interactions (56). In some forms of osteoarthritis, articular chondrocytes recapitulate the developmental processes of growth plate chondrocytes (1, 2). We have shown previously that during chondrocyte development, there is decreased RhoA activity (55) and increased expression of related proteins of the SIBLING family (28, 29). Our work implies that chondrocytes may preferentially increase their actin-based contact to matrices containing SIBLING proteins as these cells differentiate and mature. Furthermore, during dedifferentiation of chondrocytes to fibroblast-like cells in arthritis (57) or in prolonged in vitro culture (57), the basic mechanisms regulating cell shape may also change. Our work clearly demonstrates that chondrocytes and fibroblasts use Rho and ROCK in different capacities.
In summary, we show that similar to other cells [endothelial cells (5), osteoblasts (20, 53) and osteoclasts (49)] involved in endochondral ossification, growth plate chondrocytes can interact with BSP. However, chondrocytes and fibroblasts spread more on and thus have more contact with FN-coated surfaces compared with BSP-coated surfaces. We show FAK-Src signaling act as a positive regulator in controlling chondrocyte adhesion and spreading to FN and BSP. In contrast, inhibition of the Rho-ROCK pathway in chondrocytes and Rho in fibroblasts counteracts the reduced spreading on BSP, suggesting that the Rho-ROCK pathway inhibits chondrocyte spreading on BSP. Our work, to the best of our knowledge, is the first indication that classical integrin binding ECM molecules use different actin remodeling pathways to control cell shape and that these signaling pathways have unique consequences in controlling cell-matrix contact in different cell types.
| GRANTS |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| REFERENCES |
|---|
|
|
|---|
2. Appleton CT, Pitelka V, Henry J, Beier F. Global analyses of gene expression in early experimental osteoarthritis. Arthritis Rheum 56: 1854–1868, 2007.[CrossRef][Web of Science][Medline]
3. Aszodi A, Hunziker EB, Brakebusch C, Fassler R. Beta1 integrins regulate chondrocyte rotation, G1 progression, and cytokinesis. Genes Dev 17: 2465–2479, 2003.
4. Behonick DJ, Werb Z. A bit of give and take: the relationship between the extracellular matrix and the developing chondrocyte. Mech Dev 120: 1327–1336, 2003.[CrossRef][Web of Science][Medline]
5. Bellahcene A, Bonjean K, Fohr B, Fedarko NS, Robey FA, Young MF, Fisher LW, Castronovo V. Bone sialoprotein mediates human endothelial cell attachment and migration and promotes angiogenesis. Circ Res 86: 885–891, 2000.
6. Burridge K, Wennerberg K. Rho and Rac take center stage. Cell 116: 167–179, 2004.[CrossRef][Web of Science][Medline]
7. Bursell L, Woods A, James CG, Pala D, Leask A, Beier F. Src kinase inhibition promotes the chondrocyte phenotype. Arthritis Res Ther 9: R105, 2007.[CrossRef][Medline]
8. Calalb MB, Polte TR, Hanks SK. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol Cell Biol 15: 954–963, 1995.[Abstract]
9. Chen BH, Tzen JT, Bresnick AR, Chen HC. Roles of Rho-associated kinase and myosin light chain kinase in morphological and migratory defects of focal adhesion kinase-null cells. J Biol Chem 277: 33857–33863, 2002.
10. Dobereiner HG, Dubin-Thaler BJ, Giannone G, Sheetz MP. Force sensing and generation in cell phases: analyses of complex functions. J Appl Physiol 98: 1542–1546, 2005.
11. Enomoto-Iwamoto M, Iwamoto M, Nakashima K, Mukudai Y, Boettiger D, Pacifici M, Kurisu K, Suzuki F. Involvement of alpha5beta1 integrin in matrix interactions and proliferation of chondrocytes. J Bone Miner Res 12: 1124–1132, 1997.[CrossRef][Web of Science][Medline]
12. Flevaris P, Stojanovic A, Gong H, Chishti A, Welch E, Du X. A molecular switch that controls cell spreading and retraction. J Cell Biol 179: 553–565, 2007.
13. Franzen A, Heinegard D. Proteoglycans and proteins of rat bone. In: The Chemistry and Biology of Mineralized Tissues (Proceedings of the 2nd International Conference on the Chemistry and Biology of Mineralized Tissues), edited by Butler WT, Birmingham. Ebsco Media, 1984, p. 132–141.
14. Ganss B, Kim RH, Sodek J. Bone sialoprotein. Crit Rev Oral Biol Med 10: 79–98, 1999.
15. Garciadiego-Cazares D, Rosales C, Katoh M, and Chimal-Monroy J. Coordination of chondrocyte differentiation and joint formation by alpha5beta1 integrin in the developing appendicular skeleton. Development 131: 4735–4742, 2004.
16. Geneste O, Copeland JW, Treisman R. LIM kinase and diaphanous cooperate to regulate serum response factor and actin dynamics. J Cell Biol 157: 831–838, 2002.
17. Gerstenfeld LC, Shapiro FD. Expression of bone-specific genes by hypertrophic chondrocytes: implication of the complex functions of the hypertrophic chondrocyte during endochondral bone development. J Cell Biochem 62: 1–9, 1996.[CrossRef][Web of Science][Medline]
18. Goldberg HA, Sodek J. Purification of mineralized tissue-associated osteopontin. J Tissue Cult Methods 16: 211–215, 1994.[CrossRef]
19. Goldberg HA, Warner KJ, Li MC, Hunter GK. Binding of bone sialoprotein, osteopontin and synthetic polypeptides to hydroxyapatite. Connect Tissue Res 42: 25–37, 2001.[Web of Science][Medline]
20. Gordon JA, Tye CE, Sampaio AV, Underhill TM, Hunter GK, Goldberg HA. Bone sialoprotein expression enhances osteoblast differentiation and matrix mineralization in vitro. Bone 41: 462–473, 2007.[Medline]
21. Grande-Garcia A, Echarri A, Del Pozo MA. Integrin regulation of membrane domain trafficking and Rac targeting. Biochem Soc Trans 33: 609–613, 2005.[CrossRef][Web of Science][Medline]
22. Guan JL. Role of focal adhesion kinase in integrin signaling. Int J Biochem Cell Biol 29: 1085–1096, 1997.[CrossRef][Web of Science][Medline]
23. Harris NL, Rattray KR, Tye CE, Underhill TM, Somerman MJ, D'Errico JA, Chambers AF, Hunter GK, Goldberg HA. Functional analysis of bone sialoprotein: identification of the hydroxyapatite-nucleating and cell-binding domains by recombinant peptide expression and site-directed mutagenesis. Bone 27: 795–802, 2000.[Medline]
24. Hausler G, Helmreich M, Marlovits S, Egerbacher M. Integrins and extracellular matrix proteins in the human childhood and adolescent growth plate. Calcif Tissue Int 71: 212–218, 2002.[CrossRef][Web of Science][Medline]
25. Heidemann SR, Kaech S, Buxbaum RE, Matus A. Direct observations of the mechanical behaviors of the cytoskeleton in living fibroblasts. J Cell Biol 145: 109–122, 1999.
26. Horton MA, Nesbit MA, Helfrich MH. Interaction of osteopontin with osteoclast integrins. Ann NY Acad Sci 760: 190–200, 1995.[Web of Science][Medline]
27. Ilic D, Damsky CH, Yamamoto T. Focal adhesion kinase: at the crossroads of signal transduction. J Cell Sci 110: 401–407, 1997.[Abstract]
28. James CG, Appleton CT, Ulici V, Underhill TM, Beier F. Microarray analyses of gene expression during chondrocyte differentiation identifies novel regulators of hypertrophy. Mol Biol Cell 16: 5316–5333, 2005.
29. James CG, Ulici V, Tuckermann J, Underhill TM, Beier F. Expression profiling of Dexamethasone-treated primary chondrocytes identifies targets of glucocorticoid signalling in endochondral bone development. BMC Genomics 8: 205, 2007.[CrossRef][Medline]
30. Lefebvre V, Garofalo S, Zhou G, Metsaranta M, Vuorio E, De Crombrugghe B. Characterization of primary cultures of chondrocytes from type II collagen/beta-galactosidase transgenic mice. Matrix Biol 14: 329–335, 1994.[CrossRef][Web of Science][Medline]
31. Longhurst CM, Jennings LK. Integrin-mediated signal transduction. Cell Mol Life Sci 54: 514–526, 1998.[CrossRef][Web of Science][Medline]
32. Lub M, van Kooyk Y, van Vliet SJ, Figdor CG. Dual role of the actin cytoskeleton in regulating cell adhesion mediated by the integrin lymphocyte function-associated molecule-1. Mol Biol Cell 8: 341–351, 1997.[Abstract]
33. Mintz KP, Grzesik WJ, Midura RJ, Robey PG, Termine JD, Fisher LW. Purification and fragmentation of nondenatured bone sialoprotein: evidence for a cryptic, RGD-resistant cell attachment domain. J Bone Miner Res 8: 985–995, 1993.[Web of Science][Medline]
34. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6: 56–68, 2005.[CrossRef][Web of Science][Medline]
35. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 18: 516–523, 2006.[CrossRef][Web of Science][Medline]
36. Murphy-Ullrich JE. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J Clin Invest 107: 785–790, 2001.[CrossRef][Web of Science][Medline]
37. Oldberg A, Franzen A, Heinegard D, Pierschbacher M, Ruoslahti E. Identification of a bone sialoprotein receptor in osteosarcoma cells. J Biol Chem 263: 19433–19436, 1988.
38. Ory S, Munari-Silem Y, Fort P, Jurdic P. Rho and Rac exert antagonistic functions on spreading of macrophage-derived multinucleated cells and are not required for actin fiber formation. J Cell Sci 113: 1177–1188, 2000.[Abstract]
39. Pala D, Kapoor M, Woods A, Kennedy L, Liu S, Chen S, Bursell L, Lyons KM, Carter DE, Beier F, Leask A. FAK/SRC suppresses early chondrogenesis: central role of CCN2. J Biol Chem 283: 9239–9247, 2008.
40. Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci 115: 3861–3863, 2002.
41. Pertz O, Hodgson L, Klemke RL, Hahn KM. Spatiotemporal dynamics of RhoA activity in migrating cells. Nature 440: 1069–1072, 2006.[CrossRef][Medline]
42. Qin C, Baba O, Butler WT. Post-translational modifications of sibling proteins and their roles in osteogenesis and dentinogenesis. Crit Rev Oral Biol Med 15: 126–136, 2004.
43. Salih E, Fluckiger R. Complete topographical distribution of both the in vivo and in vitro phosphorylation sites of bone sialoprotein and their biological implications. J Biol Chem 279: 19808–19815, 2004.
44. Stubbs JT, 3rd Mintz KP, Eanes ED, Torchia DA, Fisher LW. Characterization of native and recombinant bone sialoprotein: delineation of the mineral-binding and cell adhesion domains and structural analysis of the RGD domain. J Bone Miner Res 12: 1210–1222, 1997.[CrossRef][Web of Science][Medline]
45. Suidan HS, Nobes CD, Hall A, Monard D. Astrocyte spreading in response to thrombin and lysophosphatidic acid is dependent on the Rho GTPase. Glia 21: 244–252, 1997.[CrossRef][Web of Science][Medline]
46. Sung V, Stubbs JT, 3rd Fisher L, Aaron AD, Thompson EW. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins. J Cell Physiol 176: 482–494, 1998.[CrossRef][Web of Science][Medline]
47. Tye CE, Hunter GK, Goldberg HA. Identification of the type I collagen-binding domain of bone sialoprotein and characterization of the mechanism of interaction. J Biol Chem 280: 13487–13492, 2005.
48. Tye CE, Rattray KR, Warner KJ, Gordon JA, Sodek J, Hunter GK, Goldberg HA. Delineation of the hydroxyapatite-nucleating domains of bone sialoprotein. J Biol Chem 278: 7949–7955, 2003.
49. Valverde P, Tu Q, Chen J. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. J Bone Miner Res 20: 1669–1679, 2005.[CrossRef][Web of Science][Medline]
50. Van Beek JP, Kennedy L, Rockel JS, Bernier SM, Leask A. The induction of CCN2 by TGFbeta1 involves Ets-1. Arthritis Res Ther 8: R36, 2006.[CrossRef][Medline]
51. Wang G, Beier F. Rac1/Cdc42 and RhoA GTPases antagonistically regulate chondrocyte proliferation, hypertrophy, and apoptosis. J Bone Miner Res 20: 1022–1031, 2005.[CrossRef][Web of Science][Medline]
52. Wang G, Woods A, Agoston H, Ulici V, Glogauer M, Beier F. Genetic ablation of Rac1 in cartilage results in chondrodysplasia. Dev Biol 306: 612–623, 2007.[CrossRef][Web of Science][Medline]
53. Wang J, Zhou HY, Salih E, Xu L, Wunderlich L, Gu X, Hofstaetter JG, Torres M, Glimcher MJ. Site-specific in vivo calcification and osteogenesis stimulated by bone sialoprotein. Calcif Tissue Int 79: 179–189, 2006.[CrossRef][Web of Science][Medline]
54. White DG, Hershey HP, Moss JJ, Daniels H, Tuan RS, Bennett VD. Functional analysis of fibronectin isoforms in chondrogenesis: full-length recombinant mesenchymal fibronectin reduces spreading and promotes condensation and chondrogenesis of limb mesenchymal cells. Differentiation 71: 251–261, 2003.[CrossRef][Web of Science][Medline]
55. Woods A, Beier F. RhoA/ROCK signaling regulates chondrogenesis in a context-dependent manner. J Biol Chem 281: 13134–13140, 2006.
56. Woods A, Wang G, Beier F. Regulation of chondrocyte differentiation by the actin cytoskeleton and adhesive interactions. J Cell Physiol 213: 1–8, 2007.[CrossRef][Web of Science][Medline]
57. Woods A, Wang G, Beier F. RhoA/ROCK signaling regulates Sox9 expression and actin organization during chondrogenesis. J Biol Chem 280: 11626–11634, 2005.
58. Woods A, Wang G, Dupuis H, Shao Z, Beier F. Rac1 signaling stimulates N-cadherin expression, mesenchymal condensation, and chondrogenesis. J Biol Chem 282: 23500–23508, 2007.
59. Wuttke M, Muller S, Nitsche DP, Paulsson M, Hanisch FG, Maurer P. Structural characterization of human recombinant and bone-derived bone sialoprotein. Functional implications for cell attachment and hydroxyapatite binding. J Biol Chem 276: 36839–36848, 2001.
60. Zaia J, Boynton R, Heinegard D, Barry F. Posttranslational modifications to human bone sialoprotein determined by mass spectrometry. Biochemistry 40: 12983–12991, 2001.[CrossRef][Web of Science][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |